In its Phase II trial, it achieved up to a 24.2% reduction in body weight, which is greater than most currently FDA approved drugs like Semaglutide
Clinical trial data from the STEP program showed that semaglutide 2.4mg weekly produced average weight loss of 14.9% of body weight over 68 weeks, compared to tirzepatide at 15mg which achieved approximately 22.5% in the SURMOUNT trials
Although insulin suppresses both GAL and NPY expression, leptin strongly inhibits NPY gene expression and release, yet produces little or no change in basal GAL expression in the ARC and only a small suppression of GAL expression in the PVN

You should definitely speak with your GP if: You have been diagnosed with type 2 diabetes or non-diabetic hyperglycaemia (pre-diabetes) and are considering supplements as an alternative or addition to prescribed treatment You are currently taking medications for diabetes, as supplements may interact and alter blood glucose control You are taking any prescribed medications, particularly anticoagulants, immunosuppressants, or medications with narrow therapeutic windows You are experiencing symptoms of poor glucose control, such as excessive thirst, frequent urination, unexplained weight loss, or fatigue You are interested in pharmaceutical GLP-1 or GIP receptor agonists for diabetes management or weight loss Seek urgent medical help via NHS 111 or 999 if you experience: Severe dehydration Abdominal pain with vomiting Deep or rapid breathing Confusion or drowsiness These could indicate a serious hyperglycaemic emergency requiring immediate treatment

Pregnancy, breastfeeding, and active gallbladder disease also warrant detailed risk-benefit discussion
doi: 10.1105/tpc.105.039339 15 ZhangTLiuRZhengJWangZGaoTQinMet al